Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9

NCT01388075 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: Rifampicin

Sponsor

Hadassah Medical Organization